王园江，校聘副教授，硕士生导师。
2021年9月在东南大学化学化工学院获得博士学位，2021.11-2024.11留在东南大学化学化工学院任教，2024.12起在南京工业大学药学院从事教学及科研工作。近年以第一作者或共通讯作者在 Acta Pharmaceutica Sinica B, Journal of Medicinal Chemistry和European Journal of Medicinal Chemistry等国内外药学一流期刊发表学术论文十余篇，申请国内外专利十余篇。主持国家自然科学基金青年基金项目，江苏省科研创新项目以及各类企业和医院的研发项目。担任Journal of Medicinal Chemistry，European Journal of Medicinal Chemistry和Bioorganic Chemistry等多个国内外期刊的审稿人。
研究方向：
1. 小分子抗肿瘤药物的设计、合成及作用机制研究
2. 分子药理学研究
3. 新型光敏剂的设计合成及应用研究
主持的科研项目：
1. 国家自然科学基金青年基金，NO. 22207015，2023.01-2025.12（主持，在研）；
2. 用于蛋白质互作研究的小分子化合物合成工艺开发，NO. 54228039，2024.12-2027.12（主持，在研）；
3. 新型活性失踪探针（红色）的设计合成与性质研究，NO. 8507048538，2024.05-2026.05（主持，在研）；
4. 诱导肿瘤干细胞分化促进放疗增敏研究，NO. 8507048540，2024.07-2027.06（主持，在研）；
5. 江苏省科研创新项目，No. KYCX19_0102，2019.05-2020.05（主持，已结题）。
近五年发表的代表性研究成果：
1. Mingwei Fu, Min Ge, Wanxiang Yang, Chunchen Hu, Xiaowei Li, Yuanjiang Wang*, and Shaohua Gou. Discovery of a potent and selective cell division cycle 7 inhibitor from 6-(3-fluoropyridin4-yl)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as an orally active antitumor agent. Acta Pharmaceutica Sinica B, 2024, 14(2), 893-896.
2. Yuanjiang Wang, Jianluo Zhang, KunLi, Shengjin Xia, and Shaohua Gou*. Multitargeting HDAC Inhibitors Containing aRAS/RAF Protein Interfering Unit. Journal of Medicinal Chemistry, 2024, 67, 2066-2082.
3. Yuanjiang Wang , Yanchang Pan , Zhaodan Lv , Shaohua Gou*, Discovery of N-(4-((6-(3,5-Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors, European Journal of Medicinal Chemistry, 2024, 271, 116415.
4. Mingwei Fu1, Yuanjiang Wang1, Min Ge, Chunchen Hu, Ya Xiao, Yan Ma, Shaohua Gou*, Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway, Bioorganic & Medicinal Chemistry Letters, 2024, 113, 129968.
5. Yuanjiang Wang, Kun Li, Wenqing Xu, Shaohua Gou*. Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors. Bioorganic Chemistry, 2023, 139, 106759.
6. Xinyi Wang, Yuanjiang Wang*, Shaohua Gou. A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition. International Journal of Biochemistry and Cell Biology, 2023, 157, 106395.
7. Yanliang Guo, Biao Gao, Peng Gao, Yuanjiang Wang*, Shaohua Gou. Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFRT790M/C797S inhibitors. Bioorganic& Medicinal Chemistry, 2023, 90, 117338.
8. Xinyi Wang, Zhikun Liu, Yuanjiang Wang*, Shaohua Gou. Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on Lung Cancer for Overcoming Drug Resistance. Journal of Medicinal Chemistry, 2022, 65, 7933-7945.
9. Yuanjiang Wang, Zhaodan Lv, Feihong Chen, Xing Wang, and Shaohua Gou*. Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition. Journal of Medicinal Chemistry, 2021, 64(8), 5082-5098.
10. Yuanjiang Wang, Xinyi Wang, Gang Xu, and Shaohua Gou*. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments. Journal of Medicinal Chemistry, 2021, 64(7), 4163-4178.
11. Yuanjiang Wang, Zhaodan Lv, Feihong Chen, Xing Wang, and Shaohua Gou*. Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Reversed Drug Resistance and Suppressed Migration and Invasion of Triple-negative Breast Cancer. Journal of Medicinal Chemistry, 2021, 64(17), 12877-12892.
12. Xing Wang1, Yuanjiang Wang1, Shaohua Gou, Feihong Chen*. A trifunctional Pt(II) complex alleviates the NHEJ/HR-related DSBs repairs to evade cisplatin-resistance in NSCLC. Bioorganic Chemistry, 2020, 104, 104210.
已申请的发明专利：
1. 拉帕替尼-癌细胞干性抑制剂偶联物、制法、药物组合物和应用，专利号： ZL 2021 1 0598974.4（已授权）
2. 具有抗人肝癌HepG2细胞活性的Tröger’s Base类衍生物合成方法，专利号：ZL 2015 1 0272697.2（已授权）
3. 六元并五元杂环化合物及其药物组合和应用，专利申请号：CN202310446452.1
4. 三环类化合物及其制备方法、药物组合物和应用，专利申请号： CN202310837130.X
5. 萘醌类化合物及其制备方法、药物组合和应用，专利申请号：CN202311058497.8
6. 具有靶向作用的铂（II）化合物及其衍生物、制备方法、药物组合物和应用，专利申请号：CN202111420868.3
7. 一类抗肿瘤化合物及其制备与用途，专利申请号：CN202010224405.9
8. Platinum (II) COMPOUND HAVING TARGETING EFFECT，专利申请号：PCT/CN2022/133430 （PCT专利）
9. ANTI-TUMOR COMPOUND CAPABLE OF OVERCOMING CISPLATIN，专利申请号：PCT/CN2021/070303（PCT专利）
10. ANTI-TUMOR COMPOUNDS, AND PREPARATION AND USE THEREOF，专利申请号：PCT/CN2021/074623（PCT专利）
E-mail: jiangluck@njtech.edu.cn
当前位置: